Biotech Pharmaceutical
RiboNova is a privately-held biopharmaceutical company based in the Lankenau Institute for Medical Research near Philadelphia, Pennsylvania.
Our product pipeline includes a Phase-2 ready small molecule drug for the treatment of all forms of genetically confirmed mitochondrial disease.
In addition to this product candidate, we have a proprietary drug discovery platform that targets transfer RNA with novel precision medicines for the treatment of mitochondrial and other diseases.